Exact Sciences Corp. Reports First-Quarter Earnings Miss

Exact Sciences Corp. (NASDAQ:EXAS) reported a first-quarter earnings miss, resulting in a 10% share price drop. Despite a net loss of $110 million, the company’s revenue exceeded expectations at $638 million. With a focus on cancer screening and diagnostic tests, Exact Sciences saw growth in Screening and Precision Oncology revenue. CEO Kevin Conroy remains optimistic about the company’s global expansion and commercial engine momentum.